This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
Burden of Disease
Burden of Disease
Risk Factors
Secondary Infections
Mechanism of Action
Prevention of Pneumococcal Disease
Need for Pneumococcal Vaccination
Cost-effectiveness of PCV13
Legacy of Prevenar
Safety
Conclusion
Dosing
Prevenar 13® Clinical Experience
Efficacy of Prevenar 13®
Effectiveness of Prevenar 13®
Indian Clinical Trials
Recommendations for Use
PCV13 in Pulmonology
PCV13 in Nephrology
PCV13 in Oncology
PCV13 in Rheumatology
PCV13 in Diabetes
PCV13 in HIV Infection
PCV13 in Cardiology
Resources
What Are the National and Global Recommendations for Pneumococcal Vaccination in Diabetics?
Patient assessment of the burden of disease due to vaccine-preventable disorders clearly shows that pneumococcal disease is the leading cause of death in all age groups, with the elderly population being the most affected. The high CFRs of bacteraemic pneumococcal diseases demand effective preventive strategies, including immunoprophylactic measures and vaccines. However, in diabetic populations, such strategies may be challenging due to the presence of immune abnormalities. The antibody response of diabetics, especially in high-risk groups, needs to be studied with various vaccination strategies. Recommendations for vaccinations are based on the main risk factors for infectious diseases such as age, the presence of chronic diseases, immunosuppression, smoking status, alcohol use and ethnic groups which include diabetes. The organisations that have issued guidelines for pneumococcal vaccination in diabetes include the ACIP, ATAGI,the Canadian National Advisory Committee on Immunization and the United Kingdom Department of Health, among several others.1-4
Various national guidelines, like the Geriatric Society of India (2015) and RSSDI (2020), recommend vaccination in diabetic patients to prevent pneumococcal diseases.5,6
The RSSDI guidelines state that6:
PCV13 is recommended for adults aged ≥50 years followed by a dose of PPSV23 at least 1 year later, (and at least 5 years after their previous PPSV23 dose) depending on the clinical judgment of the physician.
ACIP, Advisory Committee on Immunization Practices; ATAGI, Australian Technical Advisory Group on Immunisation; CFR, case fatality rate; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal plain polysaccharide vaccine; RSSDI, Research Society for Study of Diabetes in India.
References:
Please click the Prescribing Information link to view the safety and adverse events information of Prevenar 13®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-PRV-IND-0268 July 2022
Help protect your adult patients against pneumococcal pneumonia with single-dose administration
Learn more
Efficacy proven by the CAPiTA study
Learn more
The ACIP recommends routine use of PCV13 among adults
Learn more
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.